Neuroprotective effects of lipopolysaccharide and naltrexone co‑preconditioning in the photothrombotic model of unilateral selective hippocampal ischemia in rat

• Autorzy: Hosseini S.M. , Golaghaei A. , Nassireslami E. , Naderi N. , Pourbadie H.G. , Rahimzadegan M. , Mohammadi S.
• Języki publikacji: EN

Abstrakty

EN

Preconditioning with lipopolysaccharide (LPS) or opioid antagonists has a neuroprotective effect in ischemic insults. However, the co-preconditioning effect of toll-like receptor ligands and opioid antagonists has not been investigated. In this study we examined the neuroprotective effect of LPS and naltrexone (NTX) preconditioning and co-preconditioning in unilateral selective hippocampal ischemia in rats to assess for possible synergistic protective effects. LPS and NTX were injected unilaterally into the left cerebral ventricle of male rats. Forty-eight hours after LPS and twenty-four hours after NTX injection, ipsilateral selective hippocampal ischemia was induced using a modified version of the photothrombotic method. Protective effects for LPS and NTX were assessed by evaluating infarct volume (using 2,3,5-triphenyltetrazolium chloride staining), and cognitive function (using radial arm water maze and passive avoidance tests). Animals in the ischemic group had an infarct lesion and considerable cognitive impairment, compared with the sham group. LPS or NTX preconditioning significantly reduced the infarct size and improved cognitive function. Moreover, co-preconditioning with LPS and NTX increased the protective effect compared with preconditioning with LPS or NTX alone. Our data showed that LPS and NTX preconditioning resulted in a neuroprotective effect in hippocampal ischemia. Furthermore, co-preconditioning with LPS and NTX resulted in a synergistic protective effect.

• Wydawca: -
• Czasopismo: Acta Neurobiologiae Experimentalis
• Rocznik: 2019
• Tom: 79
• Numer: 1
• Opis fizyczny: p.73-85,fig.,ref.

Twórcy

autor

Hosseini S.M.

• Department of Pharmacology and Toxicology, School of Medicine, AJA University of Medical Sciences, Tehran, Iran

autor

Golaghaei A.

• Department of Pharmacology and Toxicology, School of Medicine, AJA University of Medical Sciences, Tehran, Iran

autor

Nassireslami E.

• Department of Pharmacology and Toxicology, School of Medicine, AJA University of Medical Sciences, Tehran, Iran,

autor

Naderi N.

• Department of Pharmacology and Toxicology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
• Neuroscience Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

autor

Pourbadie H.G.

• Department of Physiology and Pharmacology, Pasteur Institute of Iran, Tehran, Iran

autor

Rahimzadegan M.

• Department of Pharmacology and Toxicology, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

autor

Mohammadi S.

• Department of Pharmacology and Toxicology, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

Bibliografia

• Altermann CDC, Souza MA, Schimidt HL, Izaguirry AP, Martins A, Garcia A, Santos FW, Mello-Carpes PB (2017) Short-term green tea supplementation prevents recognition memory deficits and ameliorates hippocampal oxidative stress induced by different stroke models in rats. Brain Res Bull 131: 78–84.
• Anrather J, Iadecola C (2016) Inflammation and stroke: an overview. Neurotherapeutics 13: 661–670.
• Anttila JE, Whitaker KW, Wires ES, Harvey BK, Airavaara M (2016) Role of microglia in ischemic focal stroke and recovery: focus on Toll-like receptors. Prog Neuropsychopharmacol Biol Psychiatry 79: 3–14.
• Barth AM, Mody I (2011) Changes in hippocampal neuronal activity during and after unilateral selective hippocampal ischemia in vivo. J Neurosci 31: 851–860.
• Braida D, Paladini E, Gori E, Sala M (1997) Naltrexone, naltrindole, and CTOP block cocaine-induced sensitization to seizures and death. Peptides 18: 1189–1195.
• Brown N, Panksepp J (2009) Low-dose naltrexone for disease prevention and quality of life. Med Hypotheses 72: 333–337.
• Cant R, Dalgleish AG, Allen RL (2017) Naltrexone inhibits IL-6 and TNFα production in human immune cell subsets following stimulation with ligands for intracellular Toll-like receptors. Front Immunol 8: 809.
• Chaby LE, Sheriff MJ, Hirrlinger AM, Lim J, Fetherston TB, Braithwaite VA (2015) Does chronic unpredictable stress during adolescence affect spatial cognition in adulthood? PLoS One 10: e0141908.
• Chang RC, Rota C, Glover RE, Mason RP, Hong J-S (2000) A novel effect of an opioid receptor antagonist, naloxone, on the production of reactive oxygen species by microglia: a study by electron paramagnetic resonance spectroscopy. Brain Res 854: 224–229.
• Chen GY, Nuñez G (2010) Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol 10: 826.
• Chopra P, Cooper MS (2013) Treatment of complex regional pain syndrome (CRPS) using low dose naltrexone (LDN). J Neuroimmune Pharmacol 8: 470–476. Cree BA, Kornyeyeva E, Goodin DS (2010) Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann Neurol 68: 145–150.
• Desmond DW, Moroney JT, Sano M, Stern Y (2002) Incidence of dementia after ischemic stroke. Stroke 33: 2254–2262.
• Dirnagl U, Becker K, Meisel A (2009) Preconditioning and tolerance against cerebral ischaemia: from experimental strategies to clinical use. Lancet Neurol 8: 398–412.
• Dorr A, Sled J, Kabani N (2007) Three-dimensional cerebral vasculature of the CBA mouse brain: a magnetic resonance imaging and micro computed tomography study. Neuroimage 35: 1409–1423.
• Elliott GT (1998) Monophosphoryl lipid A induces delayed preconditioning against cardiac ischemia-reperfusion injury. J Mol Cell Cardiol 30: 3–17.
• Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA, Moran AE, Sacco RL, Anderson L, Truelsen T, O’Donnell M, Venketasubramanian N, Barker-Collo S, Lawes CM, Wang W, Shinohara Y, Witt E, Ezzati M, Naghavi M, Murray C; Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010) and the GBD Stroke Experts Group (2014) Global and regional burden of stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet 383: 245–255.
• Gong G, Bai S, Wu W, Hu L, Liu Y, Niu J, Dai X, Yin L, Wang X (2014) Lrg participates in lipopolysaccharide preconditioning-induced brain ischemia injury via TLR4 signaling pathway. J Mol Neurosci 54: 20–26.
• Gurley C, Nichols J, Liu S, Phulwani NK, Esen N, Kielian T (2008) Microglia and astrocyte activation by toll-like receptor ligands: modulation by PPAR-agonists. PPAR Res 2008: 453120 .
• Hock NH (1998) Neuroprotective agents in acute ischemic stroke. J Cardiovasc Nurs 13: 17–25.
• Hodges H, Sowinski P, Sinden J, Fletcher A, Netto C (1995) The selective 5-HT 3 receptor antagonist, WAY100289, enhances spatial memory in rats with ibotenate lesions of the forebrain cholinergic projection system. Psychopharmacology 117: 318–332.
• Hua F, Ma J, Ha T, Kelley JL, Kao RL, Schweitzer JB, Kalbfleisch JH, Williams DL, Li C (2009) Differential roles of TLR2 and TLR4 in acute focal cerebral ischemia/reperfusion injury in mice. Brain Res 1262: 100–108.
• Ji YB, Zhuang PP, Ji Z, Wu YM, Gu Y, Gao XY , Pan SJ, Hu JF (2017) TFP5 peptide, derived from CDK5-activating cofactor p35, provides neuroprotection in early-stage of adult ischemic stroke. Sci Rep 7: 40013.
• Ji Y, Hu Y, Wu Y, Ji Z, Song W, Wang S, Pan S (2012) Therapeutic time window of hypothermia is broader than cerebral artery flushing in carotid saline infusion after transient focal ischemic stroke in rats. Neurol Res 34: 657–663.
• Kalaria RN, Akinyemi R, Ihara M (2016) Stroke injury, cognitive impairment and vascular dementia. Biochim Biophys Acta 1862: 915–925.
• Kamigaki M, Hide I, Yanase Y, Shiraki H, Harada K, Tanaka Y, Hide M, Sakai N (2016) The Toll-like receptor 4-activated neuroprotective microglia subpopulation survives via granulocyte macrophage colony-stimulating factor and JAK2/STAT5 signaling. Neurochem Int 93: 82–94.
• Labat-Gest V, Tomasi S (2013) Photothrombotic ischemia: a minimally invasive and reproducible photochemical cortical lesion model for mouse stroke studies. J Vis Exp 76: 1–6.
• Lewis SS, Loram LC, Hutchinson MR, Li CM, Zhang Y, Maier SF, Huang Y, Rice KC, Watkins LR (2012) (+)-naloxone, an opioid-inactive toll-like receptor 4 signaling inhibitor, reverses multiple models of chronic neuropathic pain in rats. J Pain 13: 498–506.
• Lu N, Liu XY (2009) Naloxone hydrochloride preconditioning suppresses expressions of aquaporin protein-4 and matrix metalloproteinase-9 in rat brain tissue around cerebral hemorrhagic focus. Acta Academiae Medicinae Militaris Tertiae 21: 042.
• Marsh B, Stevens SL, Packard AE, Gopalan B, Hunter B, Leung PY, Harrington CA, Stenzel-Poore MP (2009) Systemic lipopolysaccharide protects the brain from ischemic injury by reprogramming the response of the brain to stroke: a critical role for IRF3. J Neurosci 29: 9839–9849.
• Marsh BJ, Williams-Karnesky RL, Stenzel-Poore MP (2009) Toll-like receptor signaling in endogenous neuroprotection and stroke. Neuroscience 158: 1007–1020.
• Medvedev AE, Lentschat A, Wahl LM, Golenbock DT, Vogel SN (2002) Dysregulation of LPS-induced Toll-like receptor 4-MyD88 complex formation and IL-1 receptor-associated kinase 1 activation in endotoxin-tolerant cells. J Immunol 169: 5209–5216.
• Nategh M, Nikseresht S, Khodagholi F, Motamedi F (2016) Inactivation of nucleus incertus impairs passive avoidance learning and long term potentiation of the population spike in the perforant path-dentate gyrus evoked field potentials in rats. Neurobiol Learn Mem 130: 185–193.
• O’Neill LA, Golenbock D, Bowie AG (2013) The history of Toll-like receptors - redefining innate immunity. Nat Rev Immunol 13: 453.
• Paxinos G, Watson C (2007) The Rat Brain in Stereotaxic Coordinates. 6th edn. Academic Press, San Diego.
• Rabiei Z, Rafieian-kopaei M, Heidarian E, Saghaei E, Mokhtari S (2014) Effects of Zizyphus jujube extract on memory and learning impairment induced by bilateral electric lesions of the nucleus Basalis of Meynert in rat. Neurochem Res 39: 353–360.
• Ramagiri S, Taliyan R (2017) Protective effect of remote limb post conditioning via upregulation of heme-oxygenase-1/BDNF pathway in rat model of cerebral ischemic reperfusion injury. Brain Res 1669: 44–54.
• Rosenzweig HL, Minami M, Lessov NS, Coste SC, Stevens SL, Henshall DC, Meller R, Simon RP, Stenzel-Poore MP (2007) Endotoxin preconditioning protects against the cytotoxic effects of TNFα after stroke: a novel role for TNFα in LPS-ischemic tolerance. J Cereb Blood Flow Metab 27: 1663–1674.
• Sadelli K, Stamegna JC, Girard SD, Baril N, Escoffier G, Brus M, Véron AD, Khrestchatisky M, Roman FS (2017) Global cerebral ischemia in rats leads to amnesia due to selective neuronal death followed by astroglial scar formation in the CA1 layer. Neurobiol Learn Mem 141: 168–178.
• Schaafsma W, Zhang X, Van Zomeren K, Jacobs S, Georgieva P, Wolf S, Kettenmann H, Janova H, Saiepour N, Hanisch UK, Meerlo P, van den Elsen PJ, Brouwer N, Boddeke HW, Eggen BJ (2015) Long-lasting pro-inflammatory suppression of microglia by LPS-preconditioning is mediated by RelB-dependent epigenetic silencing. Brain Behav Immun 48: 205–221.
• Schmidt A, Hoppen M, Strecker JK, Diederich K, Schäbitz WR, Schilling M, Minnerup J (2012) Photochemically induced ischemic stroke in rats. Exp Transl Stroke Med 4: 13.
• Secades JJ, Alvarez-Sabín J, Castillo J, Díez-Tejedor E, Martínez-Vila E, Ríos J, Oudovenko N (2016) Citicoline for acute ischemic stroke: a systematic review and formal meta-analysis of randomized, double-blind, and placebo-controlled trials. J Stroke Cerebrovasc Dis 25: 1984–1996.
• Smith JP, Bingaman SI, Ruggiero F, Mauger DT, Mukherjee A, McGovern CO, Zagon IS (2011) Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn’s disease: a randomized placebo-controlled trial. Dig Dis Sci 56: 2088–2097.
• Stempniak B, Forsling ML, Guzek J (1995) Intracerebroventricular insulin and release of vasopressin and oxytocin in the rat: effect of dehydration or haemorrhage. Pathophysiology 2: 115–122.
• Tang X, Zhao J, Zhang Z, Zhang X, Song S (2005) Effect of naloxone on expression of Bcl-2 protein and tumor necrosis factor-alpha in rats with acute myocardial ischemia/reperfusion injury (in Chinese). Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 17: 430–432.
• Toshchakov V, Jones BW, Perera PY, Thomas K, Cody MJ, Zhang S, Williams BR, Major J, Hamilton TA, Fenton MJ, Vogel SN (2002) TLR4, but not TLR2, mediates IFN-beta-induced STAT1alpha/beta-dependent gene expression in macrophages. Nat Immunol 3: 392.
• Valentino RJ, Katz JL, Medzihradsky F, Woods JH (1983) Receptor binding, antagonist, and withdrawal precipitating properties of opiate antagonists. Life Sci 32: 2887–2896.
• Vann KT, Xiong ZG (2016) Optogenetics for neurodegenerative diseases. Int J Physiol Pathophysiol Pharmacol 8: 1.
• Vartanian KB, Stevens SL, Marsh BJ, Williams-Karnesky R, Lessov NS, Stenzel-Poore MP (2011) LPS preconditioning redirects TLR signaling following stroke: TRIF-IRF3 plays a seminal role in mediating tolerance to ischemic injury. J Neuroinflammation 8: 140.
• Verebey K, Mule S (1975) Naltrexone pharmacology, pharmacokinetics, and metabolism: current status. Am J Drug Alcohol Abuse 2: 357–363.
• Vibulsresth S, Dietrich WD, Busto R, Ginsberg MD (1987) Failure of nimodipine to prevent ischemic neuronal damage in rats. Stroke 18: 210–216.
• Watkins L, Hutchinson M, Ledeboer A, Dodick DW (2007) Norman Cousins Lecture: Glia as the “bad guys”. Headache 47: 1272–1273.
• Watkins LR, Hutchinson MR, Ledeboer A, Wieseler-Frank J, Milligan ED, Maier SF (2007) Glia as the “bad guys”: implications for improving clinical pain control and the clinical utility of opioids. Brain Behav Immun 21: 131–146.
• Wu J, Stoica BA, Luo T, Sabirzhanov B, Zhao Z, Guanciale K, Nayar SK, Foss CA, Pomper MG, Faden AI (2014) Isolated spinal cord contusion in rats induces chronic brain neuroinflammation, neurodegeneration, and cognitive impairment: Involvement of cell cycle activation. Cell Cycle 13: 2446–2458.
• Younger J, Parkitny L, McLain D (2014) The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol 33: 451–459.

Identyfikatory

DOI

10.21307/ane‑2019‑006